(ALPHAZ)-ALPHA-(3-吡啶基亚甲基)-1H-吲哚-3-乙腈
(ALPHAZ)-ALPHA-(3-吡啶基亚甲基)-1H-吲哚-3-乙腈
(ALPHAZ)-ALPHA-(3-吡啶基亚甲基)-1H-吲哚-3-乙腈 性质
| 熔点 | 202℃ |
|---|---|
| 沸点 | 470.078±40.00 °C(Press: 760.00 Torr)(predicted) |
| 密度 | 1.280±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | DMF：30mg/mL； DMSO：30mg/mL； DMSO:PBS (pH 7.2) (1:6)：0.1 mg/ml；乙醇：0.2mg/mL |
| 形态 | 粉末 |
| 酸度系数(pKa) | 16.525±0.30(predicted) |
| 颜色 | 浅黄至黄色 |
(ALPHAZ)-ALPHA-(3-吡啶基亚甲基)-1H-吲哚-3-乙腈 用途与合成方法
|
MKLP-2 1.35 μM (IC 50 ) |
Paprotrain has been screened on a panel of CNS kinases. While inactive (IC 50 >10 μM) on CDK5 and GSK3, it has shown a moderate activity on DYRK1A (IC 50 =5.5 μM). Time-lapse microscopy shows that disrupting MKlp2 expression with paprotrain results in polar body extrusion failure. This could be rescued after rescuing oocytes from paprotrain in fresh medium. Cell cycle analysis shows that most oocytes are arrested at metaphase I or telophase I. However, oocyte spindle structure and chromosome alignment are not disrupted after the inhibition of MKlp2 by paprotrain. Paprotrain-treated porcine oocytes suffer failure of nuclear maturation. The number of oocytes arrested at early MI stage increase in a dose-dependent manner after KIF20A activity inhibition, while the percentage of oocytes that reach ATI and MII stages decrease after treatment.
(ALPHAZ)-ALPHA-(3-吡啶基亚甲基)-1H-吲哚-3-乙腈 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-101298 | (ALPHAZ)-ALPHA-(3-吡啶基亚甲基)-1H-吲哚-3-乙腈 | 57046-73-8 | 5mg | 500 |
| 2026-09-15 | HY-101298 | (ALPHAZ)-ALPHA-(3-吡啶基亚甲基)-1H-吲哚-3-乙腈 | 57046-73-8 | 10mM * 1mLin DMSO | 550 |
